Supplementary tables from: Long-term outcomes of patients diagnosed with differentiated thyroid cancer in childhood and young adulthood

Rates of pediatric differentiated thyroid cancer (DTC) in the United
States have been increasing while studies on this population remain
limited by inconsistent age cut-offs, short follow-up periods, or relative
lack of clinical data. In this manuscript, we report long-term
outcomes in patients diagnosed with DTC at age 20 years old and younger.
155 patients were included with a median age at diagnosis of 17 years (9
to 20 years). The frequency of distant metastasis and larger tumor size
were inversely related to age at diagnosis (overall stage p = 0.045,
T-stage (size of the primary tumor ± invasion) p = 0.001). The median
duration of follow-up was 16 years (1 to 63 years) and at last follow-up,
52.3% of patients had excellent response and disease specific mortality
was 0%. There was no difference in response to therapy based on histologic
subtype or birth sex; however, younger age at diagnosis was associated
with worse response (p = 0.046). Patients with over 50 years of follow-up
(n = 9) had median of 36 years of stability, with progression occurring in
6 out of 9 (67%) patients.